CLINT COOKSEY: Open Payments
NPI 1205217064 · JENA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,071 in 61 payments from 16 companies in 2025. Trend: 2023 $1,033 · 2024 $982 · 2025 $1,071
Food & beverage: $1,071
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $180 |
| ABBVIE INC. | 8 | $138 |
| Novo Nordisk Inc | 6 | $99 |
| Otsuka America Pharmaceutical, Inc. | 5 | $97 |
| Lilly USA, LLC | 5 | $82 |
| PFIZER INC. | 5 | $79 |
| Amgen Inc. | 4 | $64 |
| GlaxoSmithKline, LLC. | 4 | $62 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $50 |
Products named: REXULTI, FARXIGA, ELIQUIS, OTEZLA, TRELEGY ELLIPTA, MOUNJARO, Auvelity, VRAYLAR.
Industry payments across LA — which companies pay providers there.
